Loading company…
Meng Mou Biology develops stem cell and gene therapies for degenerative eye diseases.
Meng Mou Biology develops stem cell and gene therapies for eye diseases, using technologies including induced pluripotent stem cell differentiation and AAV vector optimization. Founded in 2023 and based in Chengdu, China, it collaborates with Beijing Tongren Hospital and Beijing Eye Institute. It received angel funding from Zhongguancun Development Venture in September 2023 and closed Pre-A1 funding in January 2026 from Future New Intelligence, IDG Capital, and Zhongguancun Development Venture.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in